Actually, It's Not About The Patient – At Least When It Comes To Product Exclusivity

Otsuka sues FDA for allowing Alkermes' ‘chemical trick’ to skirt Abilify Maintena's exclusivity, but agency says active moieties of the two drugs are not the same, regardless how they behave in patients.